WO2008005217A3 - Iron(ii)-containing treatments for hyperphosphatemia - Google Patents

Iron(ii)-containing treatments for hyperphosphatemia Download PDF

Info

Publication number
WO2008005217A3
WO2008005217A3 PCT/US2007/014688 US2007014688W WO2008005217A3 WO 2008005217 A3 WO2008005217 A3 WO 2008005217A3 US 2007014688 W US2007014688 W US 2007014688W WO 2008005217 A3 WO2008005217 A3 WO 2008005217A3
Authority
WO
WIPO (PCT)
Prior art keywords
iron
pharmaceutically acceptable
hyperphosphatemia
compound
ferrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/014688
Other languages
French (fr)
Other versions
WO2008005217A2 (en
Inventor
Chad C Huval
Pradeep K Dhal
Stephen Randall Holmes-Farley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to JP2009518197A priority Critical patent/JP2009542653A/en
Priority to EP07796408A priority patent/EP2043627A2/en
Priority to US12/307,420 priority patent/US20100135950A1/en
Publication of WO2008005217A2 publication Critical patent/WO2008005217A2/en
Publication of WO2008005217A3 publication Critical patent/WO2008005217A3/en
Anticipated expiration legal-status Critical
Priority to US13/534,672 priority patent/US20130243720A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selecte from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.
PCT/US2007/014688 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia Ceased WO2008005217A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009518197A JP2009542653A (en) 2006-07-05 2007-06-25 Iron (II) containing therapeutic agent for hyperphosphatemia
EP07796408A EP2043627A2 (en) 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia
US12/307,420 US20100135950A1 (en) 2006-07-05 2007-06-25 Iron(II)-Containing Treatments for Hyperphosphatemia
US13/534,672 US20130243720A1 (en) 2006-07-05 2012-06-27 Iron(II)-Containing A Treatments for Hyperphosphatemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81872706P 2006-07-05 2006-07-05
US60/818,727 2006-07-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/534,672 Continuation US20130243720A1 (en) 2006-07-05 2012-06-27 Iron(II)-Containing A Treatments for Hyperphosphatemia

Publications (2)

Publication Number Publication Date
WO2008005217A2 WO2008005217A2 (en) 2008-01-10
WO2008005217A3 true WO2008005217A3 (en) 2008-02-21

Family

ID=38772059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/014688 Ceased WO2008005217A2 (en) 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia

Country Status (4)

Country Link
US (2) US20100135950A1 (en)
EP (1) EP2043627A2 (en)
JP (1) JP2009542653A (en)
WO (1) WO2008005217A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1394299B1 (en) * 2009-05-12 2012-06-06 Chimico Internaz Spa Lab PROCEDURE FOR THE PREPARATION OF SEVELAMER
JP5881721B2 (en) * 2011-10-12 2016-03-09 Ｓｂｉファーマ株式会社 Improvement / prevention of chronic kidney disease
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
RU2014128587A (en) * 2011-12-13 2016-02-10 Синтон Б.В. GETTING A SEALAMER WITH A REDUCED ALLYLAMINE CONTENT
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
RS61409B1 (en) 2014-12-10 2021-03-31 Tricida Inc Proton-binding polymers for oral administration
US20190381024A1 (en) * 2015-10-27 2019-12-19 Medice Arzneimittel Putter Gmbh & Co. Kg Nicotinamide for lowering phosphate levels in hyperphosphatemia
CN109414453B (en) 2016-05-06 2023-02-17 特里赛达公司 Compositions for treating acid-base imbalances
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN120417778A (en) 2022-12-12 2025-08-01 维洛福斯股份公司 Composition for the preventive treatment of hypocalcemia in ruminants
US12150954B1 (en) 2023-11-21 2024-11-26 Protekta Inc. Composition and method for reducing risk of hypocalcemia in periparturient ruminant animals
US12310984B1 (en) 2023-11-21 2025-05-27 Protekta Inc. Composition and method for reducing risk of hypocalcemia in periparturient ruminant animals

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB2121277A (en) * 1982-06-09 1983-12-21 Dorrian Ray Duncan Barnett Preparations for combating colds and flu, containing iron salt and calcium lactate
EP1457256A1 (en) * 2001-12-21 2004-09-15 Muromachi Chemical Co., Ltd Adsorbent for phosphoric acid
WO2005092039A2 (en) * 2004-03-22 2005-10-06 Ilypsa, Inc. Crosslinked amine polymers
WO2006061336A2 (en) * 2004-12-07 2006-06-15 Vincenzo Savica Oral compositions for absorption of phosphorus compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456428A (en) * 1944-10-11 1948-12-14 Shell Dev Polyallyl amine and related polymeric amines
US3104205A (en) * 1959-12-17 1963-09-17 Warner Lambert Pharmaceutical Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid
US3308020A (en) * 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3332841A (en) * 1961-10-04 1967-07-25 Lilly Co Eli Method of treating hyperacidity
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3980770A (en) * 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
US4205064A (en) * 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4181718A (en) * 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4071478A (en) * 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
US4183918A (en) * 1977-03-08 1980-01-15 Exxon Research & Engineering Co. Detoxifying-medicinal emulsions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4344993A (en) * 1980-09-02 1982-08-17 The Dow Chemical Company Perfluorocarbon-polymeric coatings having low critical surface tensions
US4504640A (en) * 1982-05-19 1985-03-12 Nitto Boseki Co., Ltd. Process for producing monoallylamine polymer
DE3241113A1 (en) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen VACCINES WITH INGREDIENTS
JPS6090243A (en) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Small spherical crosslinked monoallylamine polymer and its preparation
CA1220897A (en) * 1984-01-11 1987-04-21 Kiyoshi Shimizu Process for producing polymers of monoallylamine
US4631305A (en) * 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
DE3541511A1 (en) * 1985-11-19 1987-05-21 Grace W R Ab PROMOTER FOR PAPER SIZING, METHOD FOR THE PRODUCTION AND USE THEREOF
US6274713B1 (en) * 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
IE914179A1 (en) * 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5055197A (en) * 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
ATE159262T1 (en) * 1992-07-22 1997-11-15 Hoechst Ag POLYVINYLAMINE DERIVATIVES HAVING HYDROPHILIC CENTERS, METHOD FOR THE PRODUCTION THEREOF AND THE USE OF THE COMPOUNDS AS MEDICINAL PRODUCTS, ACTIVE CARRIERS AND FOOD ADDITIVES
DK0580079T3 (en) * 1992-07-22 1997-06-30 Hoechst Ag Cross-linked, nitrogen-containing vinyl copolymers, processes for their preparation and use of these compounds
US5302531A (en) * 1992-10-22 1994-04-12 Miles Inc. Composition for the semiquantitative determination of specific gravity of a test sample
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5929184A (en) * 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
US5760121A (en) * 1995-06-07 1998-06-02 Amcol International Corporation Intercalates and exfoliates formed with oligomers and polymers and composite materials containing same
CN1230118A (en) * 1996-07-19 1999-09-29 日研化学株式会社 hyperphosphatemia treatment
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
DE69934536T2 (en) * 1998-04-09 2007-10-04 Nippon Shokubai Co. Ltd. Crosslinked polymer particles and process for its preparation and use
DE19835467A1 (en) * 1998-08-06 2000-02-17 Elenac Gmbh Solid reactor with antistatic coating for carrying out reactions in the gas phase
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
DE60212819T2 (en) * 2001-04-18 2006-11-23 Genzyme Corp., Cambridge SALT FORM POLYALLYLAMINE
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
WO2002085381A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for treating gout and binding uric acid
DE10297577B4 (en) * 2001-12-21 2007-11-22 Tohru Koike Zinc complexes capable of trapping substances having anionic substituents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
CA2551528A1 (en) * 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7019085B2 (en) * 2004-08-30 2006-03-28 Albright Robert L Phosphate selective resin and related methods
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB2121277A (en) * 1982-06-09 1983-12-21 Dorrian Ray Duncan Barnett Preparations for combating colds and flu, containing iron salt and calcium lactate
EP1457256A1 (en) * 2001-12-21 2004-09-15 Muromachi Chemical Co., Ltd Adsorbent for phosphoric acid
WO2005092039A2 (en) * 2004-03-22 2005-10-06 Ilypsa, Inc. Crosslinked amine polymers
WO2006061336A2 (en) * 2004-12-07 2006-06-15 Vincenzo Savica Oral compositions for absorption of phosphorus compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KURODA S ET AL: "EFFECT OF IRON AS A NEW TYPE OF PHOSPHATE BINDER IN HEMODIALYSIS PATIENTS", JAPANESE JOURNAL OF NEPHROLOGY - NIHON JINZO GAKKAISHI, NIHON JINZO GAKKAI, TOKYO, JP, vol. 8, no. 37, August 1995 (1995-08-01), pages 468 - 473, XP008002871, ISSN: 0385-2385 *

Also Published As

Publication number Publication date
US20100135950A1 (en) 2010-06-03
EP2043627A2 (en) 2009-04-08
JP2009542653A (en) 2009-12-03
US20130243720A1 (en) 2013-09-19
WO2008005217A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008005217A3 (en) Iron(ii)-containing treatments for hyperphosphatemia
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2008112565A3 (en) Method and composition for treating cancer
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
US9597406B2 (en) Controlled release method for a pharmaceutical composition composed of chelating complex micelles
MXPA06012865A (en) Permeation enhancing compositions for anticholinergic agents.
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
MY149169A (en) Method of treating cancer with a vegf antagonist and an anti-proliferative agent
NZ599284A (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
WO2008092006A3 (en) Antimicrobial compositions
WO2005046618A3 (en) Methods of treating eczema
WO2010132777A3 (en) Treatment of urinary tract infections with antibacterial aminoglycoside compounds
BRPI0413746A (en) compound or a n-oxide thereof or pharmaceutically acceptable salt thereof, composition, and method of treating hyperproliferative disorder
WO2012021796A8 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012006055A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
CA2547990A1 (en) Pharmaceutical compositions and methods for insulin treatment
WO2003092629A3 (en) Methods of simultaneously treating mucositis and fungal infection
WO2007102090A3 (en) Topical formulation
MX2013005482A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2013061328A3 (en) Methods of treating cancer
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
NZ595271A (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796408

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007796408

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009518197

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12307420

Country of ref document: US